Emer Leahy Form 3 INTENSITY THERAPEUTICS / Emer Leahy ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Leahy Emer

(Last) (First) (Middle)

C/O INTENSITY THERAPEUTICS, INC.

61 WILTON ROAD, 3RD FLOOR

(Street)

WESTPORT CT 06880

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/29/2023

3. Issuer Name and Ticker or Trading Symbol
INTENSITY THERAPEUTICS, INC. [ INTS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy Common Stock)	(1)	06/24/2026	Common Stock	10,000	4	D
Stock Option (right to buy Common Stock)	(1)	05/01/2028	Common Stock	25,000	9	D
Stock Option (right to buy Common Stock)	(1)	08/06/2029	Common Stock	7,500	9	D
Stock Option (right to buy Common Stock)	(1)	07/31/2030	Common Stock	5,250	11.5	D
Stock Option (right to buy Common Stock)	(2)	08/13/2031	Common Stock	25,000	11.5	D
Stock Option (right to buy Common Stock)	(3)	12/13/2032	Common Stock	25,000	9	D

Explanation of Responses:

1. This option is fully vested and exercisable.

2. This option is vested and exercisable with regard to 12,500 shares of Common Stock. This option will vest with regard to the remaining shares of Common Stock, subject to the individual's continued service as a director of Intensity Therapeutics, Inc., in two equal annual installments, beginning on August 13, 2023.

3. This option is vested and exercisable with regard to 6,250 shares of Common Stock. This option will vest with regard to the remaining shares of Common Stock, subject to the individual's continued service as a director of Intensity Therapeutics, Inc., in three equal annual installments, beginning on December 13, 2023.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Daniel L. Woodard, Attorney-in-Fact	06/29/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.